Low-Energy Extracorporeal Shock Wave Therapy Ameliorates Kidney Function in Diabetic Nephropathy.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
03
2019
revised:
24
05
2019
accepted:
30
05
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
23
2
2020
Statut:
epublish
Résumé
Diabetic nephropathy is the most common cause of end-stage renal disease. Traditional therapy for diabetic nephropathy has focused on supportive treatment, and there is no significant effective therapy. We investigated the effect of low-energy extracorporeal shock wave therapy on a diabetic nephropathy rat model. Streptozotocin-induced diabetic nephropathy rats were treated with six sessions of low-energy extracorporeal shock wave therapy (weekly for six consecutive weeks) or left untreated. We assessed urinary creatinine and albumin, glomerular volume, renal fibrosis, podocyte number, renal inflammation, oxidative stress, and tissue repair markers (SDF-1 and VEGF) six weeks after the completion of treatment. The six-week low-energy extracorporeal shock wave therapy regimen decreased urinary albumin excretion as well as reduced glomerular hypertrophy and renal fibrosis in the rat model of diabetic nephropathy. Moreover, low-energy extracorporeal shock wave therapy increased podocyte number in diabetic nephropathy rats. This was likely primarily attributed to the fact that low-energy extracorporeal shock wave therapy reduced renal inflammation and oxidative stress as well as increased tissue repair potency and cell proliferation. Low-energy extracorporeal shock wave therapy preserved kidney function in diabetic nephropathy. Low-energy extracorporeal shock wave therapy may serve as a novel noninvasive and effective treatment of diabetic nephropathy.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic nephropathy is the most common cause of end-stage renal disease. Traditional therapy for diabetic nephropathy has focused on supportive treatment, and there is no significant effective therapy. We investigated the effect of low-energy extracorporeal shock wave therapy on a diabetic nephropathy rat model.
METHODS
METHODS
Streptozotocin-induced diabetic nephropathy rats were treated with six sessions of low-energy extracorporeal shock wave therapy (weekly for six consecutive weeks) or left untreated. We assessed urinary creatinine and albumin, glomerular volume, renal fibrosis, podocyte number, renal inflammation, oxidative stress, and tissue repair markers (SDF-1 and VEGF) six weeks after the completion of treatment.
RESULTS
RESULTS
The six-week low-energy extracorporeal shock wave therapy regimen decreased urinary albumin excretion as well as reduced glomerular hypertrophy and renal fibrosis in the rat model of diabetic nephropathy. Moreover, low-energy extracorporeal shock wave therapy increased podocyte number in diabetic nephropathy rats. This was likely primarily attributed to the fact that low-energy extracorporeal shock wave therapy reduced renal inflammation and oxidative stress as well as increased tissue repair potency and cell proliferation.
CONCLUSIONS
CONCLUSIONS
Low-energy extracorporeal shock wave therapy preserved kidney function in diabetic nephropathy. Low-energy extracorporeal shock wave therapy may serve as a novel noninvasive and effective treatment of diabetic nephropathy.
Identifiants
pubmed: 31354913
doi: 10.1155/2019/8259645
pmc: PMC6637677
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8259645Références
Clin Orthop Relat Res. 2001 Jun;(387):8-17
pubmed: 11400898
Diabetes. 2003 Oct;52(10):2603-14
pubmed: 14514646
J Orthop Res. 2003 Nov;21(6):984-9
pubmed: 14554209
J Orthop Res. 2004 May;22(3):526-34
pubmed: 15099631
Kidney Int. 1992 Apr;41(4):1085-9
pubmed: 1513090
FEBS Lett. 2005 Dec 19;579(30):6839-45
pubmed: 16325181
Coron Artery Dis. 2006 Feb;17(1):63-70
pubmed: 16374144
Circulation. 2006 Dec 19;114(25):2823-30
pubmed: 17145991
Nephrology (Carlton). 2007 Jun;12(3):261-6
pubmed: 17498121
J Am Soc Nephrol. 2008 Mar;19(3):433-42
pubmed: 18256353
Int Braz J Urol. 2008 Jan-Feb;34(1):91-6
pubmed: 18341726
J Dent Res. 2008 Jul;87(7):687-91
pubmed: 18573992
Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):444-52
pubmed: 18607402
Curr Med Chem. 2009;16(19):2366-72
pubmed: 19601786
Cardiology. 2010;115(2):130-44
pubmed: 19955748
J Am Soc Nephrol. 2010 Jan;21(1):124-35
pubmed: 20019166
J Am Soc Nephrol. 2010 Apr;21(4):556-63
pubmed: 20167701
Nat Rev Nephrol. 2010 Sep;6(9):508-10
pubmed: 20736983
Mol Med. 2011 Jan-Feb;17(1-2):59-69
pubmed: 20844835
Annu Rev Pathol. 2011;6:395-423
pubmed: 21261520
Nat Rev Nephrol. 2011 Jun;7(6):327-40
pubmed: 21537349
Am J Transl Res. 2011 May 15;3(3):259-68
pubmed: 21633631
PLoS One. 2011;6(9):e24342
pubmed: 21915315
Nat Rev Nephrol. 2011 Nov 01;8(1):52-6
pubmed: 22045242
Int J Mol Med. 2012 Jul;30(1):85-92
pubmed: 22552764
Exp Neurol. 2012 Aug;236(2):363-70
pubmed: 22575596
Muscle Nerve. 2013 May;47(5):702-10
pubmed: 23505053
J Diabetes Res. 2013;2013:248563
pubmed: 23862164
J Am Soc Nephrol. 2015 Feb;26(2):328-38
pubmed: 25183809
Circ J. 2014;78(12):2915-25
pubmed: 25274132
Int J Nephrol Renovasc Dis. 2014 Oct 15;7:361-81
pubmed: 25342915
Am J Transl Res. 2014 Nov 22;6(6):631-48
pubmed: 25628776
Kidney Int. 2015 Nov;88(5):1099-107
pubmed: 26376129
Sci Rep. 2015 Dec 10;5:17637
pubmed: 26656101
J Gastroenterol Hepatol. 2019 Apr;34(4):720-727
pubmed: 29966170
Nephrol Dial Transplant. 2018 Dec 22;:null
pubmed: 30590575
Clin Exp Nephrol. 2019 May;23(5):597-605
pubmed: 30617840